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Abstract 
Purpose: To investigate whether siRNA targeting viral protein 5 (VP5) can become a new treatment for 
herpes simplex virus type 1 (HSV-1). 
Methods: Flow cytometry was performed to determine the ratio of siRNA and lipo2000 to reach the 
highest transfection efficiency. Western blot and q-PCR were performed to determine the knockdown 
efficiency of siRNA targeting UL19, as well as changes in cytoskeleton proteins. Plaque reduction 
assays and confocal microscopy were conducted to test the influence of VP5 knockdown on the HSV-1 
life cycle and viral replication. F-actin organization was observed through confocal microscopy during 
HSV-1 infection when transfected with siRNA.  
Results: Relative expression level of the UL19 gene dropped to 6 % while plaque formation inhibition 
rate rose to 85 % compared with virus control. Knocking down VP5 expression abrogated the changes 
to F-actin that were induced by HSV-1 infection.  
Conclusion: Interfering with UL19 gene expression inhibits HSV-1 replication efficiently in vitro. The 
results indicate that the major capsid protein VP5 encoding gene UL19 may be a promising target for 
RNA interference-based therapeutic strategy against HSV-1. 
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Herpes simplex virus type 1 (HSV-1), a 
neurotropic alpha – herpes virus, is a linear 
double-stranded DNA virus that occurs naturally 
in humans [1]. It can lead to a number of mild to 
severe diseases, and could even be life 
threatening when patients are immuno-
compromised [2]. Aciclovir® (ACV) and other 
related nucleoside analogs have been approved 
worldwide for the treatment of the virus [3]. 
However, problems associated with toxicity and 
drug resistance have been reported [4]. 
Currently, there is no specific drug available for 
eliminating latent herpes simplex virus infections 
[5]. Therefore, the need for new, safe and 
effective antiviral drugs is imperative. 
 
The viral caspid is an important structural 
component of HSV-1 virus particles. It plays a 
critical role in viral replication, assembly, 
maturation and infection. Assembly of 
herpesvirus capsids takes place in the nucleus. 
The procapsid is formed and the viral genome is 
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then packaged into it. The mature HSV-1 capsid 
comprises four proteins (VP5, VP23, VP19C and 
VP26) and is shaped like an icosahedral shell. It 
consists of 162 capsomeres, including 150 
hexons, 11 pentons and one portal that consists 
of a dodecamer of UL16. VP5, encoded by the 
UL19 gene, is the major structural protein of 
hexons and pentons [6], and acts as a scaffold 
during the formation of the HSV-1 capsid. It also 
recruits other capsid proteins to the icosahedron 
and is a major antigenic component [7]. 
Interactions have been detected between VP5 
and the scaffold protein, triplex protein and 
VP26. This interaction is important for closure of 
the capsid shell into an icosahedral structure [8]. 
These findings suggest that VP5 are necessary 
for HSV-1 to proliferate, and open up the 
possibility that VP5 could be a new target in anti-
HSV therapies. 
 
The use of RNA interference (RNAi) techniques 
could be a novel approach for anti-HSV therapies 
[9]. RNAi involves gene-silencing based on 
sequence-specific targeting and post-
transcriptional mRNA degradation, induced by 
double-stranded RNAs [10]. Short interfering 
RNAs (siRNAs), generated by the ribonuclease 
III enzyme Dicer, that are 21-25 nucleotides act 
as functional intermediates in RNAi for inducing 
target mRNA cleavage by the RNA-induced 
silencing complex (RISC) [11]. This powerful 
technology has been widely used to manipulate 
gene expression, identify gene functions on a 
whole-genome scale, and develop antiviral 
strategies for the prevention and treatment of 
human viral diseases [12]. To date, RNAi has 
been employed against several human 
pathogens, including human immunodeficiency 
virus type 1, hepatitis C virus, hepatitis B virus, 
poliovirus, influenza virus A and Dengue virus 
[13]. In our current study, we applied siRNAs 
targeting UL19 of HSV-1 to investigate the 






African green monkey kidney cells (Vero; ATCC 
CCL81), provided by the Wuhan Institute of 
Virology at the Chinese Academy of Sciences 
were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10 % fetal 
calf serum (FCS) at 37 °C/5 % CO2. HSV-1 strain 
F (ATCC VR-733) was obtained from Hong Kong 
University and propagated in Vero cells, then 
stored at -80 °C until required. Virus titers were 
determined using plaque assays. The primary 
antibodies used included a mouse monoclonal 
antibody (MAb) against the HSV-1 ICP5 major 
capsid protein (3B6; Abcam), an anti-cofilin rabbit 
antibody (3312; Cell Signaling Technology), an 
anti-p-cofilin rabbit antibody (3313: Cell Signaling 
Technology), an anti-GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) rabbit MAb (14C10; 
Cell Signaling Technology). The secondary 
antibodies used included Alexa Fluor 488-
conjugated goat anti-mouse IgG (H + L) 
(Invitrogen), Alexa Fluor 633-conjugated goat 




Lipofectanmine® RNAiMAX (Invitrogen, 
Carlsbad, California, America) was used to 
introduce siRNAs into cells. For transfection with 
the siRNA duplexes, vero cells were seeded into 
24-well plates (8 × 104 cells/well) and incubated 
at 37 °C overnight. When the cultures reached 
90 % confluence, the siRNA duplex was mixed 
with lipofectamine RNAiMAX and added to the 
culture medium. After 4 h, cells were washed 
with phosphate-buffered saline (PBS) and 
overlaid with 200 μl of virus diluent to achieve a 
multiplicity of infection (MOI) of 5 for 1.5 h. Cells 
were then washed and DMEM containing 2 % 
FCS. The UL19 siRNA duplexes were 5′-CUU 
CGC UGA UGA ACG UUG ATT-3′ (sense) and 
5′-UCA ACG UUC AUC AGC GAA GGG-3′ 
(antisense). The scrambled siRNA duplexes 
were 5′-UUC UCC GAA CGU GUC ACG UTT-3′ 
(sense) and 5′-AGG UGA CAC GUU CGG AGA 
ATT-3′ (antisense); these did not target any 
known genes and were used as negative 
controls. All siRNAs were synthesized by 
Shanghai GenePharma Co Ltd. 
 
RNA isolation, reverse transcription, and real-
time quantitative PCR (qPCR) 
 
Vero cells were grown in 6-well plates to 70-80 % 
confluence, then transfected with the various 
siRNAs (200 pmol) using lipofectamine 
RNAiMAX. After 4-6 h, cells were infected with 
HSV-1 at an MOI of 5. After 24 h, total RNA from 
infected cells was extracted using Trizol 
(Invitrogen). RNA concentrations were measured 
using a spectrophotometer (Beckman) at 
wavelengths of 260 and 280 nm. Extracted RNA 
(1 μg) was reverse-transcribed into cDNA using 
a PrimeScript RT reagent Kit (Takara). The 
qPCR assays were conducted using SsoFast™ 
EvaGreen® Supermix (Bio-Rad) according to the 
manufacturer’s instructions. Primer pairs used 
were specific for cofilin1 (5′-GCC AGA CAA GGA 
CTG CCG CT-3′ and 5′-TCG GGG GCC CAG 
AAG ATG AAC A-3′), UL19 (5′-GAC CGA CGG 
GTG CGT TAT T-3′ and 5′-GAA GGA GTC 
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GCCATT TAG CC-3′), and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH; 5′-CAC 
CAC CAA CTG CTT AGC C-3′ and 5′-CAG TGG 




Total proteins were extracted from cells using a 
RIPA total protein lysate kit, according to the 
manufacturer’s instructions. Cell extracts were 
electrophoresed by 12 % sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), 
then transferred to a polyvinylidene fluoride 
membrane (PVDF; Immobilon). After membranes 
were blocked with 5 % (w/v) non-fat dry milk 
(Difco) in TBS-T (137 mM NaCl, 20 mM Tris, and 
0.1 % (v/v) Tween-20) at room temperature for 1 
h, they were washed three times for 5 min with 
TBS-T. Membranes were incubated with 
appropriate primary antibodies diluted in TBS-T 
at 4 °C overnight and washed three times for 5 
min with TBS-T. The membranes were then 
incubated with secondary antibodies at room 
temperature for 1 h and washed three times for 5 
min with TBS-T. Positive signals were detected 
using enhanced chemiluminescence (ECL) 
reagents (Pierce, Rockford, IL). Differences in 





Vero cells were grown in 24-well plates to 70 % 
confluence, and then transfected with the various 
siRNAs (40 pmol) using lipofectamine RNAiMAX. 
After 4 h, cells were infected with 30 plaque-
forming units (PFUs) of HSV-1 strain F. The virus 
suspension was discarded 2 h later and cells 
washed with PBS, then overlaid with 1 ml of a 
1:1 mixture of sodium carboxymethylcellulose 
(NaCMC) and DMEM lacking serum. At 72 h 
post-infection, plates were fixed with 10 % 
paraformaldehyde for 15 min and stained with 1 
% crystal violet for 20 min. Plaques were 
enumerated in each well, overlapping plaques 
and plaques at the edges of a well were counted 




Flow cytometry (FCM) was used to test the 
transfection efficiency of siRNAs. After 
transfection with FAM labeled scrambled siRNA 
duplexes (F: 5′-UUC UCC GAA CGU GUC ACG 
UTT-3′ and R: 5′-AGG UGA CAC GUU CGG 
AGA ATT-3′) for 6 h, cells were washed with 
PBS and fixed for 5 min in 4 % formaldehyde - 
PBS. The fluorescence was then analyzed with a 





Cells were seeded in 10-mm culture dishes and 
grown to 70 % confluence for siRNA transfection 
and HSV-1 infection at an MOI of 10. Cells were 
fixed with 4 % paraformaldehyde for 15 min, 
permeabilized with 0.1 % Triton X-100 for 5 min 
and blocked with 5 % bovine serum albumin 
(BSA) for 1 h. The Cells were then incubated 
with an appropriate primary antibody at room 
temperature, washed three times with PBS, and 
incubated with an Alexa Fluor 647-conjugated 
secondary antibody (1:1000 dilution) in 5 % BSA 
for 1 h at room temperature. Cells were washed 
three times with PBS, then TRITC-phalloidin and 
DAPI were used to label F-actin and cell nuclei, 
respectively. Fluorescence images were 
acquired using a confocal laser-scanning 




The results are expressed as mean ± S.D. 
Statistical significance was determined using 





VP5 knockdown inhibits HSV-1 proliferation 
 
The most efficient transfection rate was obtained 
using 10 pmol of siRNA mixed with 2 µl of 
lipofectamine RNAiMAX per square centimeter 
(Fig 1A). UL19 gene expression was inhibited by 
about 94 % (Fig 1B), and no influence was 
detected upon the other virus genes. Western 
blot analysis showed that the protein levels of 
VP5 were reduced to 18 % (Fig 1C). HSV-1 
proliferation was significantly reduced (Fig 1D) 
and viral replication was apparently inhibited (Fig 
2). At 16 h post-infection, VP5 was expressed at 
high levels and virus particle has begun to move 
from the nucleus to the cytoplasm. When the 
expression of VP5 was blocked by siRNAs, 
packaging of the virus in the nucleus was 
interrupted (Fig 2). 
 
VP5 knockdown affects the depolymerization 
of F-actin 
 
Distinct F-actin organization was observed during 
HSV-1 infection (Fig 3). The stress fiber was 
destroyed, appearing as sparse dots and with an 
irregular morphology. However, knockdown of 
VP5 expression abrogated the changes to F-
actin that were induced by HSV-1 infection. HSV-
1 infection adversely affected the filamentary  
Ma et al 





Figure 1: Knockdown of the VP5 major capsid protein using specific siRNAs. (A) Efficiency of transfection was 
assessed with flow cytometry. (B) Relative expression levels of UL19 was measured by qPCR. (C) Western 
blotting was conducted to determine silencing efficiency following transfection with siRNAs and infection with 




Figure 2: Knockdown of VP5 inhibits HSV-1 proliferation. Proliferation of HSV-1 (MOI = 10) in vero cells was 
observed using laser-scanning confocal microscopy. Vero (top), HSV-1 (middle), and siRNA (bottom). VP5 was 
detected using an anti-VP5 antibody (green), while F-actin was stained with TRITC-phalloidin (red), and nuclei 
stained with DAPI (blue). Bar, 20 µm 
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structures of F-actin, with the stress fibers in the 
nucleus becoming depolymerized. Following 
RNAi, the number of virus particles had 
decreased and the actin cytoskeleton appeared 
to be normal. 
 
VP5 knockdown affects expression of 
cytoskeletal regulators 
 
We used qPCR assays to determine the 
influence of VP5 down-regulation on the 
expression of genes related to cytoskeletal 
modulation. We assessed gene expression 
levels at 6 (early stage) and 12 h (late stage) 
post-infection, and found that UL19 expression 
was inhibited by 81 % and 85 %, respectively 
(Fig 4A). The expression of cofilin1 increased in 
conjunction with HSV-1 proliferation, but was 
decreased in the siRNA group (Fig 4B). The 
increase in cofilin1 expression promoted the 
depolymerization of F-actin, which was inhibited 
by siRNAs. In addition, western blotting was 
conducted to examine the expression levels of 
major cytoskeleton-related proteins (cofilin1, p-
cofilin1, β-actin) during HSV-1 infection. At 6 h 
post-infection, the quantities of cofilin1 and p-
cofilin1 had decreased. In the siRNA group, the 
decreases were to levels below those of the virus 
control. At 12 h post-infection, total expression 
levels for cofilin and p-cofilin1 were up-regulated 
compared with those at 6 h post-infection. 
However, this trend was not significant for the 
siRNA group (Figure 4C). These results show 
that the siRNAs targeting VP5 influenced 
changes in cytoskeleton proteins during 





In this study we evaluated the inhibitory effects of 
siRNA duplexes, specific for HSV-1 VP5, on 
HSV-1 replication and the cytoskeleton of cells. 
The siRNAs targeting UL19 were able to 
specifically and efficiently down-regulate VP5. 
Following transfection of the siRNAs, the 
proliferation and packaging of HSV-1 in the 




Figure 3: VP5 influences the depolymerization of F-actin following HSV-1 infection. F-actin (red), VP5 (green), 
and nuclei (blue). Bar, 10 µm 
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Figure 4: VP5 knockdown affects the expression of genes that regulate the cytoskeleton and affects 
rearrangement of the cytoskeleton. Cells transfected with siRNA were infected with HSV-1 (MOI = 5) over various 
durations (6 h and 12 h). Relative mRNA expression levels of UL19 (A) and cofilin1 (B) were determined by 
qPCR. (C) Western blotting was used to determine the protein expression levels of cofilin1 and p-cofilin1 
 
VP5 abrogated changes in F-actin that were 
induced by HSV-1 infection. This knockdown 
influenced changes in cytoskeleton proteins 
during retrograde transport [14], and could 
possibly lead to alterations in some cytoskeletal 
proteins following infection with HSV-1. 
 
VP5 is a major capsid protein synthesized during 
the latter phases of HSV-1 gene expression. It is 
thought to be essential for the formation of the 
capsid [15]. This capsid protein plays a key role 
in HSV-1 packaging and maturity. Previous 
studies have shown that HSV-1 strains with 
mutated forms of VP5 fail to form plaques in cell 
lines [16]. These findings suggest that VP5 is 
necessary for HSV-1 to proliferate, and opens up 
the possibility that VP5 could be a new target in 
anti-HS-1 therapies [17]. 
 
RNAi has become an advanced tool for 
screening and identifying gene function. It may 
also play an important role in antiviral defense, 
with inhibition of viral replication demonstrated in 
vitro for a variety of RNA viruses, including 
rotaviruses, respiratory syncitial virus, and 
Dengue virus. The use of RNAi in the treatment 
of HSV infections is a definite possibility. 
Although siRNAs appear to have great promise 
in antiviral therapy, this technology has several 
limitations for clinical applications. Delivery of 
siRNAs is the biggest obstacle to the 
development of siRNA-based therapeutic agents 
[18]. Direct administration would require siRNAs 
that are modified to be resistant to nucleases, 
and perhaps conjugated with a ligand to target 
the siRNA to specific tissues. Additionally, there 
are problems related to the identification of 
effective target sites within the target gene, along 
with activation of interferons triggered by siRNAs, 





The findings of this study show that siRNAs 
targeting VP5 confers excellent antiviral activity 
by inhibiting HSV-1 replication in cells. The 
findings also indicate that major capsid protein 
VP5 encoding gene UL19 may be a potential 
target for an RNA interference-based therapeutic 
strategy against HSV-1. 
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